Opinion

Mark Lanasa: The data we presented at ESMO are only the beginning of our story in solid tumors

Photo of Mark Lanasa taken from BeiGene.com

Oct 29, 2023, 17:37

Mark Lanasa: The data we presented at ESMO are only the beginning of our story in solid tumors

Mark Lanasa, at BeiGene, shared on LinkedIn:

“I had the privilege of attending ESMO – European Society for Medical Oncology Congress in Madrid, where I caught up with some of my brilliant BeiGene colleagues, surrounded myself with incredible Spanish food and architecture, and immersed myself in the latest advancements in cancer research. As an oncologist, I always find it inspiring to have the opportunity to attend these conferences and connect with other researchers, clinicians and patient advocates, all with a collective mission to revolutionize cancer care. I was impressed by how different perspectives could come together to spark new ideas and approaches to cancer care. I was energized to hear about some of the latest research and progress for patients, and I came back feeling optimistic about the work so many of us are doing to relieve the burden of cancer, and proud of BeiGene’s role in these efforts to help patients worldwide.

One of the highlights for me was the opportunity to talk to attendees about positive results from two important late-breaking presentations of data in disease areas with high unmet need—gastric cancer and non-small cell lung cancer. Gastric cancer affects millions globally, while lung cancer is the most common cancer type and leading cause of cancer-related deaths worldwide. Innovative interventions are needed to improve patient outcomes. Through these trials and others, we have demonstrated the ability to deliver clinically meaningful improvement in survival and quality of life for cancer patients. The emerging data from our solid tumor pipeline continue to be positive with all Phase 3 studies meeting their primary endpoint to-date, including across multiple tumor types and disease settings. We continue to work hard to further our development program to make treatment options accessible for people living with cancer around the world.

We believe in the power of science and that novel approaches are key in the continuing fight against cancer for everyone impacted. The data we presented at ESMO are only the beginning of our story in solid tumors. At BeiGene, we aspire to advance the science and medicine and improve upon the current standards of care by exploring combinations and stimulating the immune system with other immuno-oncology agents or diversifying with targeted treatment modalities.

I’m grateful to have represented BeiGene at this global meeting and even more grateful to all the other attendees who shared their ideas and innovations for patients. I enjoyed sharing news of challenges, successes and new approaches with colleagues who brought so many different perspectives to our common mission. We all have a part to play in advancing the fight against cancer together, and events like the ESMO Congress are an important part of that mission.”

Source: Mark Lanasa/LinkedIn.